Autoimmune gastritis in autoimmune thyroid disease.

Area of Science:

• Gastroenterology
• Endocrinology
• Immunology

Background:

• Autoimmune gastritis is linked to gastric cancer risk.
• Co-occurrence of autoimmune gastritis and autoimmune thyroid disease is documented.
• Oxyntic gastric atrophy is a key feature of autoimmune gastritis.

Purpose of the Study:

• Evaluate serum pepsinogens for identifying oxyntic gastric atrophy in autoimmune thyroid disease patients.
• Determine the association between Helicobacter pylori and oxyntic gastric atrophy in this cohort.
• Assess the utility of serological markers for gastric atrophy detection.

Main Methods:

• Case-control study comparing autoimmune thyroid disease patients with controls.
• Serum pepsinogen I and II levels used to define oxyntic gastric atrophy.
• Serological testing for H. pylori, CagA, and parietal cell antibodies performed.
• Endoscopy with biopsies offered for histological confirmation.

Main Results:

• Oxyntic gastric atrophy detected in 23.5% of autoimmune thyroid disease patients, confirmed histologically.
• High association with parietal cell antibodies (89%), low with H. pylori (11%).
• Gastric atrophy extended to the antrum in 50% of autoimmune gastritis cases.

Conclusions:

• High seroprevalence of oxyntic gastric atrophy in autoimmune thyroid disease necessitates routine serum pepsinogen testing.
• H. pylori infection is not a major contributor to gastric atrophy in this context.
• Autoimmune gastritis progression involves spread from oxyntic to antral mucosa.